getinge ab-b shs (GETIB:Stockholm)
getinge ab-b shs (GETIB) Snapshot
|
Open
kr199.00
|
Previous Close
kr199.50
|
|
|
Day High
kr199.40
|
Day Low
kr197.70
|
|
|
52 Week High
01/3/13 - kr225.10
|
52 Week Low
06/28/12 - kr165.40
|
|
|
Market Cap
47.5B
|
Average Volume 10 Days
475.1K
|
|
|
EPS TTM
kr9.58
|
Shares Outstanding
222.4M
|
|
|
EX-Date
03/22/13
|
P/E TM
20.8x
|
|
|
Dividend
kr4.15
|
Dividend Yield
2.08%
|
Related News
getinge ab-b shs (GETIB) Related Businessweek News
No Related Businessweek News Foundgetinge ab-b shs (GETIB) Details
Getinge AB, a medical technology company, engages in the provision of medical technical equipment for surgery, intensive care, infection control, and care ergonomics primarily in Western Europe, the United States, and Canada. The company operates in three segments: Medical Systems, Extended Care, and Infection Control. The Medical Systems segment offers surgical workstation systems and products under the Maquet brand for cardio surgery and intensive care. Its product portfolio includes surgical tables, surgical lamps, telemedicine, and perfusion products, instruments for bypass operations, ventilators, anaesthesia systems, and synthetic vascular implants and stents. The Extended Care segment provides systems for hygiene and the lifting of elderly and disabled persons, as well as products that prevent and treat pressure ulcers under the ArjoHuntleigh brand name. This segment offers bathing and shower solutions, lifting equipment, and mattresses for the treatment and prevention of pressure sores, as well as consulting services. The Infection Control segment supplies systems for preventing the occurrence and spread of infection under the Getinge brand name. Its product range includes disinfectors, sterilizers, documentation systems, IT systems, and related equipment. This segment serves hospitals and homes for the elderly, the pharmaceuticals industry, and laboratories. The company was founded in 1904 and is headquartered in Getinge, Sweden.
getinge ab-b shs (GETIB) Key Developments
Getinge AB reported consolidated and parent earnings results for the first quarter ended March 31, 2013. For the quarter, on consolidated basis, the company's net sales were SEK 5,664 million against SEK 5,246 million last year. Operating profit was SEK 400 million against SEK 704 million last year. Profit before tax was SEK 252 million against SEK 570 million last year. Net profit attributable to parent company's shareholders was SEK 182 million against SEK 420 million last year. Earnings per share were SEK 0.76 against SEK 1.76 last year. EBITDA was SEK 862 million against SEK 1,123 million last year. Cash flow from operations SEK 366 million against SEK 722 million last year. Investments in tangible fixed assets were SEK 200 million against SEK 166 million last year. Net interest-bearing debt was SEK 18,395 million against SEK 16,325 million at March 31, 2012. EBITA before restructuring, integration and acquisition costs was SEK 792 million against SEK 854 million last year. EBITA was SEK 551 million against SEK 854 million last year. Return on equity was 15.2% against 17.2% last year. EBITA was charged with SEK 130 million from the effects of the recently introduced Medical Device Tax in the US and the adverse exchange-rate effects in the wake of the SEK's continued rise against most currencies. Excluding the tax and negative exchange-rate effects, the group's EBITA rose by nearly 8%. For the quarter, on parent basis, the company's operating loss was SEK 33 million against SEK 26 million last year. Profit after financial items was SEK 80 million against SEK 255 million last year. Profit before tax was SEK 80 million against SEK 255 million last year. Net profit was SEK 77 million against SEK 185 million last year. In 2013, overall, organic volume growth is expected to remain in line with that of 2012 or possibly somewhat better. Profit growth, excluding restructuring costs, is expected to be favorable in the current year, even in consideration of the introduction of the Medical Device Tax in the US at year-end 2012 and negative transaction effects, which, when combined, are expected to total SEK 230 million.
Getinge AB, Q1 2013 Earnings Call, Apr 17, 2013
Getinge AB announced that at the AGM held on March 21, 2013, the shareholders resolved to declare a dividend of SEK 4.15 per share. March 26, 2013 was determined as record date for dividend.
| Recently Viewed | |||
| GETIB:SS | kr199.40 SEK | -0.10 | |
| Company | Last | Change |
| CareFusion Corp | $34.13 USD | +0.03 |
| CR Bard Inc | $106.71 USD | -0.26 |
| Hospira Inc | $35.92 USD | -0.11 |
| Mettler-Toledo International Inc | $223.39 USD | +0.28 |
| Varian Medical Systems Inc | $69.88 USD | +0.43 |
| View Industry Companies | ||
Industry Analysis
GETIB
Industry Average
| Valuation | GETIB | Industry Range |
| Price/Earnings | 20.4x |
|
| Price/Sales | 1.9x |
|
| Price/Book | 3.1x |
|
| Price/Cash Flow | 19.1x |
|
| TEV/Sales | 1.7x |
|
Post a JobJobs
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
- Northglenn, CO | Office DepotPosted: Mar 01
Sponsored Financial Commentaries
Sponsored Links
To contact GETINGE AB-B SHS, please visit www.getingegroup.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.








